iRadimed shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 GAAP EPS guidance and sale guidance above estimates. Also, the company raised its FY25 guidance above estimates.

2025-08-02 01:21

iRadimed股價在該公司報告好於預期的第二季度財務業績併發布第三季度GAAP每股收益指引和高於預期的銷售指引后走高。此外，該公司還將25財年指引上調至高於預期。